Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.02, 7.01, 9.01 · 8-K

Kardigan, Inc.

KARDNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Doug Giordano On September 29, 2026, Doug Giordano resigned from the board of directors (the “Board”) of Kardigan, Inc. (the “Company”) and his position on the Audit Committee of the Board (the “Audit Committee”). Mr.…

Filed Sep 30, 2026Accepted Sep 30, 2026, 8:01 AM EDTCIK 2123613Accession 0001193125-26-408348
Share

Company context

Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Our mission is to develop multiple targeted cardiovascular treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve. We leverage deep domain expertise in cardiovascular biology, patient data, and advanced analytics to accelerate drug discovery and development, aiming to deliver impactful therapies efficiently and at scale.

Current securities

Recent company filings

  1. SCHEDULE 13D/A - filed by PERCEPTIVE ADVISORS LLC regarding Kardigan, Inc.Oct 1, 2026
  2. SCHEDULE 13G - filed by Edelberg Jay regarding Kardigan, Inc.Aug 13, 2026
  3. 10-Q filingAug 11, 2026
  4. Results of Operations and Financial ConditionAug 11, 2026
  5. 4 filingJun 24, 2026

Registered securities in this filing

Kardigan, Inc. · 8-K · Filed 2026-09-30

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.00001 par value per share

Symbol
KARD
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: C_1b9e955d-8094-40da-b496-781a7b1d1e4c

Dimensions: Not supplied

Accession 000119312526408348 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 5.02, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Doug Giordano On September 29, 2026, Doug Giordano resigned from the board of directors (the “Board”) of Kardigan, Inc. (the “Company”) and his position on the Audit Committee of the Board (the “Audit Committee”). Mr. Giordano advised the Company that his decision to resign was not the result of any disagreement with the Company or its management on any matter relating to the Company’s operations, policies or practices. Appointment of Kristin Reinke On September 29, 2026, the Board, upon the recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Kristin Reinke to serve as a Class I director, to hold office until the Company’s annual meeting of stockholders in 2027 or until her earlier death, resignation or removal, effective as of September 29, 2026 (the “Appointment Date”). In addition, Ms. Reinke will serve as the chair of the Audit Committee. The Board has determined that Ms. Reinke is independent under the applicable listing standards of the Nasdaq Global Market and qualifies as a “financial expert” pursuant to the Securities and Exchange Commission rules. David Meeker will remain a member of the Audit Committee following such appointment. Ms. Reinke currently serves as Vice President of Finance at Google LLC (“Google”), a subsidiary of Alphabet Inc., and has been a foundational member of Google’s finance leadership team since 2005. Ms. Reinke has held various roles of increasing responsibilities while at Google and was instrumental in scaling the company from its early post-IPO growth into a multibillion-dollar enterprise. Ms. Reinke earned her Bachelor of Arts in Accounting from Michigan State University and is a Certified Public Accountant. In connection with her appointment to the Board, Ms. Reinke will receive an initial new director grant of non-qualified stock options valued at $650,000, and cash compensation for her Board and committee service, in accordance with the Company’s Non-Employee Director Compensation Policy, as such policy may be amended from time to time. There are no arrangements or understandings between Ms. Reinke and any other person pursuant to which she was selected to serve on the Board. There are no transactions in which the Company or any of its subsidiaries is a party and in which Ms. Reinke has a material interest subject to disclosure under Item 404(a) of Regulation S-K. In addition, Ms. Reinke entered into an indemnification agreement with the Company consistent with the form of indemnification agreement, a copy of which has been previously filed with the Company’s most recent Quarterly Report on Form 10-Q.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On September 30, 2026, the Company issued a press release announcing the appointment of Kristin Reinke to the Board. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Exchange Act.
Filed exhibits (1)
EX-99.1 (by filename) ck0002123613-ex99_1.htm

Exhibit 99.1 PRESS RELEASE Kardigan Announces Appointment of Kristin Reinke to its Board of Directors SOUTH SAN FRANCISCO, Calif., and PRINCETON, N.J., September 30, 2026 - Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a precision cardiovascular company, announced today the appointment of Kristin Reinke to its Board of Directors, where she will serve as chair of the Audit Committee. As part of the Board’s public company evolution, Doug Giordano will be stepping down from the Board. Both Ms. Reinke’s appointment and Mr. Giordano’s departure are effective as of September 29, 2026. “Kristin's proven track record leading AI-driven transformation at global scale will be a great asset to help us achieve our mission of changing the future of cardiovascular care. Her experience turning technology into an operational advantage will be invaluable as we integrate Prolaio's data and analytics platform into our product development, and her financial governance expertise will help guide our late-stage pipeline toward potential commercialization. We're thrilled to welcome Kristin to the Kardigan Board and are fortunate to have her chair our Audit Committee,” said Tassos Gianakakos, co-founder…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.